Neumora’s stumble is the latest setback for a once-promising class of brain drugs. Elsewhere, a cell therapy manufacturing specialist took steps toward an IPO and J&J made its latest U.S investment.
An article from
News roundup
Neumora’s stumble is the latest setback for a once-promising class of brain drugs. Elsewhere, a cell therapy manufacturing specialist took steps toward an IPO and J&J made its latest U.S investment.
Published June 16, 2026
Getty Images
Neumora drug fails two more Phase 3 trials, biotech to lay off 35% of staff
Penny Stock Neumora Therapeutics Cuts Workforce After Depression Trials Fail - Neumora Therapeutics (NASD
ARCH-launched Neumora stops depression program
Novartis doubles down on molecular glue strategy
J&J eyes rare disease expansion for blockbuster-to-be Imaavy with trial win
Neumora Therapeutics will discontinue its lead depression drug after two Phase 3 failures and lay off about 35% of its employees.
Neumora Therapeutics ends navacaprant development after Phase 3 depression trial setbacks, cuts workforce by 35%.
Alzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The Readout
Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?
Revolution and Tango yield promising cancer results, Incyte buys bleeding disorder drug, and more biotech news
A new AI model to improve trial enrollment, importing drugs from Canada, and more biotech news from The Readout
